[
  {
    "ts": null,
    "headline": "Earnings live: TSMC profit surges, CSX and Interactive Brokers Q3 results beat estimates",
    "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=7fa7cc50a2fa24b7712fd58e77c4f665c22d8c05607d82776b7eeec8312045b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760647356,
      "headline": "Earnings live: TSMC profit surges, CSX and Interactive Brokers Q3 results beat estimates",
      "id": 137120808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=7fa7cc50a2fa24b7712fd58e77c4f665c22d8c05607d82776b7eeec8312045b2"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Stock Deathmatch: Aristocrats, Kings, Zombies or REITs? Reliable Income vs. Yield Chasing",
    "summary": "Not all dividend stocks are created equal, and in this quick lesson, Rick Orford explains the difference between popular types of income-generating investments.",
    "url": "https://finnhub.io/api/news?id=cdba6932ca52ff41439ae97227c8711de749e87334b66379791085ef3378232a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760634786,
      "headline": "Dividend Stock Deathmatch: Aristocrats, Kings, Zombies or REITs? Reliable Income vs. Yield Chasing",
      "id": 137121849,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Not all dividend stocks are created equal, and in this quick lesson, Rick Orford explains the difference between popular types of income-generating investments.",
      "url": "https://finnhub.io/api/news?id=cdba6932ca52ff41439ae97227c8711de749e87334b66379791085ef3378232a"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories stock underperforms Thursday when compared to competitors",
    "summary": "Abbott Laboratories stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=27081df54f3cdadacbc0a47582bca9fa21d8eebcbfc1795e37c08083ee17404b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760632320,
      "headline": "Abbott Laboratories stock underperforms Thursday when compared to competitors",
      "id": 137137577,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=27081df54f3cdadacbc0a47582bca9fa21d8eebcbfc1795e37c08083ee17404b"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs' Business Momentum Intact Despite Mixed Q3, RBC Says",
    "summary": "Abbott Laboratories' (ABT) underlying business momentum is intact heading into 2026 despite mixed Q3",
    "url": "https://finnhub.io/api/news?id=292031afeb2fc874b98c9dcadc6336f7536b73cd0f8a3388c1634b38d5196531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760628687,
      "headline": "Abbott Labs' Business Momentum Intact Despite Mixed Q3, RBC Says",
      "id": 137106235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories' (ABT) underlying business momentum is intact heading into 2026 despite mixed Q3",
      "url": "https://finnhub.io/api/news?id=292031afeb2fc874b98c9dcadc6336f7536b73cd0f8a3388c1634b38d5196531"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: TSMC profit surges amid 'strong' AI demand, Charles Schwab stock ticks higher, United slips",
    "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=9154a5d441e744ac2bad3d3ad0a49edf4048b5907d7375e0b559593567a6cc01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760615413,
      "headline": "Earnings live: TSMC profit surges amid 'strong' AI demand, Charles Schwab stock ticks higher, United slips",
      "id": 137104988,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=9154a5d441e744ac2bad3d3ad0a49edf4048b5907d7375e0b559593567a6cc01"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: TSMC profit surges amid 'strong' AI demand, Charles Schwab stock rises, United slips premarket",
    "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=2996fc78076758f9dd5561004ee2fd29fba0eafd2d44d521d446900c398a6d9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760615413,
      "headline": "Earnings live: TSMC profit surges amid 'strong' AI demand, Charles Schwab stock rises, United slips premarket",
      "id": 137104411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=2996fc78076758f9dd5561004ee2fd29fba0eafd2d44d521d446900c398a6d9b"
    }
  },
  {
    "ts": null,
    "headline": "Abbott’s strong Q3 medtech performance offset by diagnostic weakness",
    "summary": "Abbott narrowly missed analysts’ expectations of $11.4bn for Q3 2025, with diminished Covid-19 test demand and China headwinds impacting overall performance.",
    "url": "https://finnhub.io/api/news?id=2f57108d10b8bbc38d4159729e73c0273870dab7e4d1dd1864d8af01048a7a66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760615340,
      "headline": "Abbott’s strong Q3 medtech performance offset by diagnostic weakness",
      "id": 137104532,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott narrowly missed analysts’ expectations of $11.4bn for Q3 2025, with diminished Covid-19 test demand and China headwinds impacting overall performance.",
      "url": "https://finnhub.io/api/news?id=2f57108d10b8bbc38d4159729e73c0273870dab7e4d1dd1864d8af01048a7a66"
    }
  },
  {
    "ts": null,
    "headline": "BTIG Reiterates Abbott Laboratories (ABT) Buy Recommendation",
    "summary": "BTIG Reiterates Abbott Laboratories (ABT) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=9fa240be79ce1a160220fb78c6fae16cd14a4127c94b27f73d1d15d49433b951",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760615282,
      "headline": "BTIG Reiterates Abbott Laboratories (ABT) Buy Recommendation",
      "id": 137104090,
      "image": "",
      "related": "ABT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9fa240be79ce1a160220fb78c6fae16cd14a4127c94b27f73d1d15d49433b951"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds",
    "summary": "Abbottâs strong Q3, global diversification, and resilient portfolio support long-term growth despite diagnostics softness and China risks. Read why ABT stock is a buy.",
    "url": "https://finnhub.io/api/news?id=e2ac9a0f15429b7c5dcdf565544084d411a73d398b42b29e4fca952ee0ae1883",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760613536,
      "headline": "Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds",
      "id": 137105999,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399813281/image_1399813281.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Abbottâs strong Q3, global diversification, and resilient portfolio support long-term growth despite diagnostics softness and China risks. Read why ABT stock is a buy.",
      "url": "https://finnhub.io/api/news?id=e2ac9a0f15429b7c5dcdf565544084d411a73d398b42b29e4fca952ee0ae1883"
    }
  },
  {
    "ts": null,
    "headline": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.",
    "summary": "Investors should be able to count on these stocks to deliver steady and growing income over the long term.",
    "url": "https://finnhub.io/api/news?id=7e4800b5ba3d8b3036f1e4db47b26b94b80d7f16abe3b07b08340919642c68aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760611500,
      "headline": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.",
      "id": 137104447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Investors should be able to count on these stocks to deliver steady and growing income over the long term.",
      "url": "https://finnhub.io/api/news?id=7e4800b5ba3d8b3036f1e4db47b26b94b80d7f16abe3b07b08340919642c68aa"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Oct 16, 2025",
    "summary": "Companies In The News Are: HWC, PGR, ABT, ASML.",
    "url": "https://finnhub.io/api/news?id=534c503f0752d05db632a9b5ea0d55f8ff6e118dce9bef9539f40296223871dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760608680,
      "headline": "Company News for Oct 16, 2025",
      "id": 137104534,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Companies In The News Are: HWC, PGR, ABT, ASML.",
      "url": "https://finnhub.io/api/news?id=534c503f0752d05db632a9b5ea0d55f8ff6e118dce9bef9539f40296223871dd"
    }
  },
  {
    "ts": null,
    "headline": "Sepsis Diagnostics Research Report 2025: Global Market to Reach $1.39 Billion by 2029 - Increased Adoption of Point-of-care Testing and Strategic Collaborations Boosting Growth",
    "summary": "The global sepsis diagnostics market, valued at USD 835.40 million in 2023, is projected to reach USD 1.39 billion by 2029, driven by advancements in healthcare infrastructure and awareness of sepsis, a critical life-threatening condition. The market is expected to grow at a CAGR of approximately 9% from 2024 to 2029, with increased adoption of point-of-care testing and strategic collaborations boosting growth. Key segments include microbiology, molecular diagnostics, and point-of-care tests, wi",
    "url": "https://finnhub.io/api/news?id=c6d878ee125ff6cd429e3e054eb877892c04354f2593d4de4e62b60ee50a65b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760605740,
      "headline": "Sepsis Diagnostics Research Report 2025: Global Market to Reach $1.39 Billion by 2029 - Increased Adoption of Point-of-care Testing and Strategic Collaborations Boosting Growth",
      "id": 137104535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The global sepsis diagnostics market, valued at USD 835.40 million in 2023, is projected to reach USD 1.39 billion by 2029, driven by advancements in healthcare infrastructure and awareness of sepsis, a critical life-threatening condition. The market is expected to grow at a CAGR of approximately 9% from 2024 to 2029, with increased adoption of point-of-care testing and strategic collaborations boosting growth. Key segments include microbiology, molecular diagnostics, and point-of-care tests, wi",
      "url": "https://finnhub.io/api/news?id=c6d878ee125ff6cd429e3e054eb877892c04354f2593d4de4e62b60ee50a65b6"
    }
  },
  {
    "ts": null,
    "headline": "ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook",
    "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30 per share was in line with analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=7cfe77a870e4fab561b38bb0a6b6074fd936dc64e85285f4538fa043fa01421d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760592716,
      "headline": "ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook",
      "id": 137104536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30 per share was in line with analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=7cfe77a870e4fab561b38bb0a6b6074fd936dc64e85285f4538fa043fa01421d"
    }
  },
  {
    "ts": null,
    "headline": "Abbott (ABT) Margin Surge Reinforces Bullish Narratives Despite Earnings Decline Forecast",
    "summary": "Abbott Laboratories (ABT) reported net profit margins of 31.8%, a significant jump from last year’s 14%. EPS grew sharply over the past year, up 142%, well above its five-year average annual growth rate of 18.1%. Despite this exceptional profit performance, the earnings outlook now points to a forecast decline of 7.1% per year over the next three years, setting up a tension between recent growth and future expectations. See our full analysis for Abbott Laboratories. Next, we will put these...",
    "url": "https://finnhub.io/api/news?id=f32c57414cc5f8b61a58810e8a3c044d8d5f1010b377638c099a8fc7b42aa9bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760574629,
      "headline": "Abbott (ABT) Margin Surge Reinforces Bullish Narratives Despite Earnings Decline Forecast",
      "id": 137102008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) reported net profit margins of 31.8%, a significant jump from last year’s 14%. EPS grew sharply over the past year, up 142%, well above its five-year average annual growth rate of 18.1%. Despite this exceptional profit performance, the earnings outlook now points to a forecast decline of 7.1% per year over the next three years, setting up a tension between recent growth and future expectations. See our full analysis for Abbott Laboratories. Next, we will put these...",
      "url": "https://finnhub.io/api/news?id=f32c57414cc5f8b61a58810e8a3c044d8d5f1010b377638c099a8fc7b42aa9bf"
    }
  }
]